Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26259338 | 0.82 | IMPDH2 (0.41) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL26259346 | 0.80 | ALDH1A1 (0.41) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL26259342 | 0.80 | ACHE (0.41) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL2873052 | 0.80 | TSHR (0.56) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL4124570 | 0.80 | HSD17B10 (0.46) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL2220947 | 0.78 | HSD17B10 (0.59) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL19798864 | 0.78 | HSD17B10 (0.44) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL15910481 | 0.78 | HSD17B10 (0.44) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL9624177 | 0.78 | HSD17B10 (0.44) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL7529007 | 0.78 | HSD17B10 (0.44) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2489660-A1 | Methods for making central nervous system agents that are TRPV1 antagonists | Abbott Laboratories (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8232411-B2 | Methods for making central nervous system agents that are TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2323989-A2 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100016611-A1 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009117626-A2 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016611-A1 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | TRPV1, TRPV2, OPRL1 | HSD17B10 2358/4885ALDH1A1 499/4885TSHR 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.